193 related articles for article (PubMed ID: 23185260)
1. Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy.
Barthélémy I; Uriarte A; Drougard C; Unterfinger Y; Thibaud JL; Blot S
PLoS One; 2012; 7(11):e48478. PubMed ID: 23185260
[TBL] [Abstract][Full Text] [Related]
2. Gait characterization in golden retriever muscular dystrophy dogs using linear discriminant analysis.
Fraysse B; Barthélémy I; Qannari EM; Rouger K; Thorin C; Blot S; Le Guiner C; Chérel Y; Hogrel JY
BMC Musculoskelet Disord; 2017 Apr; 18(1):153. PubMed ID: 28403854
[TBL] [Abstract][Full Text] [Related]
3. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
[TBL] [Abstract][Full Text] [Related]
4. The golden retriever model of Duchenne muscular dystrophy.
Kornegay JN
Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
[TBL] [Abstract][Full Text] [Related]
5. Gait analysis using accelerometry in dystrophin-deficient dogs.
Barthélémy I; Barrey E; Thibaud JL; Uriarte A; Voit T; Blot S; Hogrel JY
Neuromuscul Disord; 2009 Nov; 19(11):788-96. PubMed ID: 19800232
[TBL] [Abstract][Full Text] [Related]
6. Expiratory dysfunction in young dogs with golden retriever muscular dystrophy.
Hawkins EC; Bettis AK; Kornegay JN
Neuromuscul Disord; 2020 Nov; 30(11):930-937. PubMed ID: 33071066
[TBL] [Abstract][Full Text] [Related]
7. Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy.
Barthélémy I; Pinto-Mariz F; Yada E; Desquilbet L; Savino W; Silva-Barbosa SD; Faussat AM; Mouly V; Voit T; Blot S; Butler-Browne G
Dis Model Mech; 2014 Nov; 7(11):1253-61. PubMed ID: 25261568
[TBL] [Abstract][Full Text] [Related]
8. Use of the six-minute walk test to characterize golden retriever muscular dystrophy.
Acosta AR; Van Wie E; Stoughton WB; Bettis AK; Barnett HH; LaBrie NR; Balog-Alvarez CJ; Nghiem PP; Cummings KJ; Kornegay JN
Neuromuscul Disord; 2016 Dec; 26(12):865-872. PubMed ID: 27818009
[TBL] [Abstract][Full Text] [Related]
9. Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements.
Kornegay JN; Bogan JR; Bogan DJ; Childers MK; Grange RW
Methods Mol Biol; 2011; 709():105-23. PubMed ID: 21194024
[TBL] [Abstract][Full Text] [Related]
10. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.
Kornegay JN; Bogan JR; Bogan DJ; Childers MK; Li J; Nghiem P; Detwiler DA; Larsen CA; Grange RW; Bhavaraju-Sanka RK; Tou S; Keene BP; Howard JF; Wang J; Fan Z; Schatzberg SJ; Styner MA; Flanigan KM; Xiao X; Hoffman EP
Mamm Genome; 2012 Feb; 23(1-2):85-108. PubMed ID: 22218699
[TBL] [Abstract][Full Text] [Related]
11. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
[TBL] [Abstract][Full Text] [Related]
12. Transplantation of Human Adipose Mesenchymal Stem Cells in Non-Immunosuppressed GRMD Dogs is a Safe Procedure.
Pelatti MV; Gomes JP; Vieira NM; Cangussu E; Landini V; Andrade T; Sartori M; Petrus L; Zatz M
Stem Cell Rev Rep; 2016 Aug; 12(4):448-53. PubMed ID: 27193781
[TBL] [Abstract][Full Text] [Related]
13. Physical therapy assessment tools to evaluate disease progression and phenotype variability in Golden Retriever muscular dystrophy.
Gaiad TP; Silva MB; Silva GC; Caromano FA; Miglino MA; Ambrósio CE
Res Vet Sci; 2011 Oct; 91(2):188-93. PubMed ID: 21315399
[TBL] [Abstract][Full Text] [Related]
14. Motor physical therapy affects muscle collagen type I and decreases gait speed in dystrophin-deficient dogs.
Gaiad TP; Araujo KP; Serrão JC; Miglino MA; Ambrósio CE
PLoS One; 2014; 9(4):e93500. PubMed ID: 24713872
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.
Araujo KP; Bonuccelli G; Duarte CN; Gaiad TP; Moreira DF; Feder D; Belizario JE; Miglino MA; Lisanti MP; Ambrosio CE
PLoS One; 2013; 8(4):e61367. PubMed ID: 23579193
[TBL] [Abstract][Full Text] [Related]
16. Natural History of Cardiomyopathy in Adult Dogs With Golden Retriever Muscular Dystrophy.
Guo LJ; Soslow JH; Bettis AK; Nghiem PP; Cummings KJ; Lenox MW; Miller MW; Kornegay JN; Spurney CF
J Am Heart Assoc; 2019 Aug; 8(16):e012443. PubMed ID: 31411085
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.
Kornegay JN; Spurney CF; Nghiem PP; Brinkmeyer-Langford CL; Hoffman EP; Nagaraju K
ILAR J; 2014; 55(1):119-49. PubMed ID: 24936034
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.
Brinkmeyer-Langford C; Chu C; Balog-Alvarez C; Yu X; Cai JJ; Nabity M; Kornegay JN
PLoS One; 2018; 13(3):e0194485. PubMed ID: 29554127
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy.
Brinkmeyer-Langford C; Balog-Alvarez C; Cai JJ; Davis BW; Kornegay JN
BMC Genomics; 2016 Aug; 17(1):665. PubMed ID: 27549615
[TBL] [Abstract][Full Text] [Related]
20. Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ.
Shimatsu Y; Yoshimura M; Yuasa K; Urasawa N; Tomohiro M; Nakura M; Tanigawa M; Nakamura A; Takeda S
Acta Myol; 2005 Oct; 24(2):145-54. PubMed ID: 16550932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
